• Opdivo for Head-Neck Cancers Too Costly for UK Patients, NICE Rules
  • Ignyta’s RXDX-106 Works with Immune Checkpoint Inhibitors to Kill Tumors, Study Shows
  • Tecentriq Granted Accelerated Approval for Certain Advanced Bladder Cancer Patients
  • Opdivo Fails to Demonstrate Survival Benefit in Phase 3 Brain Cancer Trial
  • Oncolytics Working on Reolysin Immunotherapy Applications After Good Breast Cancer Results
  • Bayer Ends Partnership with OncoMed on Compounds That Inhibit Cancer Stem Cell Pathways
  • FDA Grants Orphan Drug Designation to NantCell’s Ganitumab to Treat Ewing Sarcoma
  • SY-1425 May Work in Combo with Approved Therapies in Leukemia Patients, Others with Blood Disorders
  • First Patient Dosed in Phase 1 Trial of Individualized Cancer Vaccine AutoSynVax
  • Immunotherapy, OSE-172, Seen to Be Safe and Effective in Mouse Models of Liver Cancer
  • Novartis Gets Closer to FDA Approval of Its CTL019 Therapy for Certain Leukemia Patients
  • Fred Hutchinson Researchers Present New Findings on Cancer Immunotherapy